Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
182.74
-3.85 (-2.06%)
At close: Aug 6, 2025, 4:00 PM
182.60
-0.14 (-0.08%)
After-hours: Aug 6, 2025, 4:29 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 17 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $222.71, which forecasts a 21.87% increase in the stock price over the next year. The lowest target is $153 and the highest is $289.
Price Target: $222.71 (+21.87%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 7 | 9 | 9 | 10 | 10 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 16 | 16 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $245 → $254 | Buy | Maintains | $245 → $254 | +39.00% | Jul 29, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $213 → $243 | Strong Buy | Maintains | $213 → $243 | +32.98% | Jul 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $250 | Buy | Initiates | $250 | +36.81% | Jul 3, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $215 → $224 | Buy | Maintains | $215 → $224 | +22.58% | Jun 13, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $201 → $216 | Strong Buy | Maintains | $201 → $216 | +18.20% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
652.19M
from 363.64M
Increased by 79.35%
Revenue Next Year
1.15B
from 652.19M
Increased by 76.18%
EPS This Year
-4.20
from -6.53
EPS Next Year
1.20
from -4.20
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 842.1M | 1.6B | 2.6B | ||
| Avg | 652.2M | 1.1B | 1.8B | ||
| Low | 513.8M | 836.1M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.6% | 151.5% | 124.2% | ||
| Avg | 79.3% | 76.2% | 53.4% | ||
| Low | 41.3% | 28.2% | 9.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.91 | 6.06 | 12.57 | ||
| Avg | -4.20 | 1.20 | 7.30 | ||
| Low | -7.53 | -3.05 | 1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 950.0% | ||
| Avg | - | - | 510.1% | ||
| Low | - | - | 66.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.